ReHeva Biosciences has concluded the Phase I clinical trial of its investigational drug, RH324, for the treatment of advanced non-small cell lung cancer (NSCLC).

The trial analysed the tolerability and safety of increasing doses of RH324 in advanced NSCLC patients who have failed treatments previously.

ReHeva carried out the trial in partnership with Case Comprehensive Cancer Center University Hospitals and Case Western Reserve University in Cleveland, US.

ReHeva Biosciences CEO, co-founder, and chief scientific officer Dr Zeenia Kaul said: “At ReHeva, we are driven by a steadfast belief that cancer treatment can be transformed to help patients live longer and healthier with cancer.

“The completion of our Phase I clinical trial represents a tremendous milestone toward realising this vision.

“By maximising the potential of plant-derived agents to target multiple tissues and mechanisms of action, we are advancing the narrative of cancer treatment.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

In 2018, the company obtained approval for an investigational new drug (IND) application from the Food and Drug Administration (FDA) for the trial.

With the trial completion, potential Phase II trials of RH324 for the treatment of various cancer types will be explored.

It will also aid in moving towards the goal of attaining FDA approval for RH324 in this indication.

With wide-ranging potential benefits, RH324 could act on various pathways linked to cancer progression.

The company earlier raised more than $7m in a funding round.